Asylum Research Announces the Hire of Scientist Florian Johann
News Aug 08, 2013
As part of its ongoing expansion, Asylum Research has introduced Florian Johann as its newest Applications Scientist.
Johann will be based in the Mannheim, Germany office and will support customers throughout Germany and continental Europe.
“We are very excited about adding Florian Johann to the outstanding list of talented Applications Scientists at Asylum in general and specifically here at our office in Germany,” said Ludger Weisser, Director of European Sales for Asylum Research Germany.
Weisser continued, “His AFM background in materials science will complement the research that is being done on next-generation materials by leading labs throughout Germany and Europe. Florian will also enable us to expand the personalized applications support that we offer to all of our customers."
"Our goal is to expand our scientific staff in the region to provide the best, most comprehensive customer service, support and accessibility to our customers," commented Roger Proksch, President of Asylum Research. "Florian will enable us to continue to build our strong partnerships in the region, with great science being the ultimate result."
Asylum Research, the technology leader in atomic force microscopy, has a worldwide presence with subsidiaries in the Germany, UK, and Taiwan.
Its product line of scanning probe/atomic force microscopes, including the Cypher™ and MFP-3D™ AFM family, has set the industry standard for technological innovation for both imaging and characterizing many properties of surfaces and structures at the nanoscale.
Its AFM/SPMs are used by academic and industrial customers across the world for a wide range of materials and bioscience applications.
Combating Cancer by Targeting Sugar ReceptorsNews
Globally, cancer is the second leading cause of death, also because the efficiency of chemotherapeutics is inadequate due to poor delivery to the tumor. Prof. Olivia Merkel and her team develop targeted nanocarrier systems to increase the delivery rates of therapeutic formulations and their specific uptake into the target cells.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018